Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study

Figure 2 Comparison of virological response rates between tenofovir amibufenamide and tenofovir alafenamide. A: Virological response (VR) rates of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) groups at 24 and 48 wk; B: VR rates of TMF and TAF groups at 24 and 48 wk with low-level viremia; C: VR rates of TMF and TAF groups at 24 and 48 wk with hepatitis B e antigen (HBeAg) negative; D: VR rates of TMF and TAF groups at 24 and 48 wk with HBeAg positive. TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; VR: Virological response; HBeAg: Hepatitis B e antigen.